Navigation Links
A*STAR partners Roche to develop new cancer therapeutics
Date:7/14/2014

SingaporeA*STAR's Bioprocessing Technology Institute (BTI) has entered into an agreement with one of the world's largest pharmaceutical company, Roche, to identify novel drug candidates for the detection and treatment of cancer. The partnership brings together BTI's capabilities in novel antibody discovery and Roche's expertise in developing monoclonal antibody (mAbs) therapeutics, opening up the possibility of improved treatment for cancer, a leading cause of death worldwide.

The collaboration makes use of BTI's discovery of a new mechanism where antibodies can directly target and destroy cancer cells, which has the potential for an entirely new class of cancer treatment. Cancer cells may be distinguished from normal cells by their elevated levels of sugar on the cell surface. The mAbs discovered and generated by BTI are able to recognise these sugar targets and allow more accurate identification of cancer cells as compared to traditional antibodies that only target proteins. mAbs generated by BTI are also unique in having a novel mechanism of action; they cause pores to form on the surface of cancer cells, leading to cell degradation and the eventual death of these diseased cells.

Dr Andre Choo, Principal Scientist at BTI and lead investigator for the project, said, "It is exciting to be able to generate a new class of mAbs that can specifically recognise sugars and lead to rapid death of diseased cells. This opens up new strategies to target and kill cancer cells."

Based on this discovery, scientists from BTI have developed a pipeline of mAbs for major cancers found in Singapore. The partnership with Roche will allow new diagnostic tests and cancer treatments to be developed more quickly and to be brought earlier to patient care. Such treatments could complement and augment existing cancer drugs and result in more effective and safer treatments for cancer patients.

Prof Lam Kong Peng, Executive Director of BTI, said, "This collaboration underscores the effectiveness of BTI's antibody research and allows us to leverage on Roche's expertise to develop novel antibody-based therapeutics. We are confident that this will be the start of a long and fruitful partnership that will not only benefit human health but also the biologics industry."

Dr. Juan-Carlos Lopez, Head of the Roche Pharma Research and Early Development Academic Relations and Collaborations, said: "Accessing external innovation through partnerships with public sector research institutes is crucial for identifying first-in-class or best-in-class opportunities. Bringing together the know-how of BTI and the expertise of Roche increases the chance of success in developing novel antibody-based therapeutics targeting both cancer and cancer stem cells which have the potential to revolutionize how we treat cancer."


'/>"/>

Contact: Vanessa Loh
vanessa_loh@a-star.edu.sg
Biomedical Sciences Institutes (BMSI)
Source:Eurekalert  

Related medicine news :

1. A*STAR scientists discover switch to boost anti-viral response to fight infectious diseases
2. Fruit flies light the way for A*STAR scientists to pinpoint genetic changes that spell cancer
3. A*STAR scientists identify potential drug target for inflammatory diseases including cancers
4. Singapore scientists led by A*STARs GIS identify 4 mechanisms that contribute to gastric cancers
5. A*STAR scientists discover switch critical to wound healing
6. A*STAR scientist Alex Matter awarded prestigious Szent-Györgyi Prize for progress in cancer
7. A*STAR scientist wins European Molecular Biology Organization Young Investigator award
8. A*STAR scientists uncover potential drug target to nip cancer in the bud
9. A*STAR scientists bring to light mechanism of drug for infections
10. Women With Older Partners More Often Admitted to Nursing Homes
11. University of Houston Graduate College of Social Work announces partnership with MD Anderson
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
A*STAR partners Roche to develop new cancer therapeutics
(Date:2/20/2017)... , ... February 20, 2017 , ... Researchers at the ... cancer, as well as a marker that may predict response to a particular class ... other types of cancer as well. The new findings were published in Proceedings of ...
(Date:2/20/2017)... ... February 20, 2017 , ... ... announced Biscom Document Router (BDR), the first IoT device from Biscom designed to ... imaging. Biscom will debut BDR at HIMSS17 and will be conducting ...
(Date:2/20/2017)... (PRWEB) , ... February 20, 2017 , ... ReportingMD, a Population Health Software Company, is ... of the company. The new location will triple the size of the previous location ... the town of Sunapee, NH. , “We are excited to expand our footprint ...
(Date:2/20/2017)... ... ... Chuck E. Cheese’s® and Center for Autism and Related Disorders (CARD) recently announced ... throughout New England, New York and New Jersey to provide children with autism spectrum ... Chuck E. Cheese’s in a sensory-friendly environment. , After a successful pilot run ...
(Date:2/19/2017)... Carolina (PRWEB) , ... February 19, 2017 , ... The ... evening undergraduate nursing students, is being led by Amelia Joseph, Ph.D. Joseph was engaged ... initial operations of the nursing department in early 2016. After a nation-wide search, she ...
Breaking Medicine News(10 mins):
(Date:2/20/2017)... Fla. , Feb. 20, 2017 Seal ... its health IT solution for mobile device management and ... 2017 HIMSS Conference and Exhibition in Orlando, ... #4444. Mobile devices have become commonplace in ... comes a new set of concerns, including the disinfection ...
(Date:2/20/2017)... -- Research and Markets has announced the addition of ... Trends - Product (RFID refrigerators and RFID freezers), Application (Diagnostic centers, ... their offering. ... The Global RFID Blood Refrigerator and Freezer Market is poised to ... This industry report analyzes the global markets for ...
(Date:2/20/2017)... FRANCISCO , February 20, 2017 ... expected to reach USD 58.4 billion by 2025, ... Research, Inc. The market is driven by technological ... serve future growth opportunities to the market. For ... with an aim of identifying emerging viruses and ...
Breaking Medicine Technology: